Aligos raises >$100M, posts Q1 net income $43.1M; HBV drug Phase 2 to start mid-2025

Aligos Therapeutics, Inc.

2025-Q1 EPS reported -$2.11 revenue$311,000

Cash grew to $137.9M after raising over $100M; expected to fund operations into H2 2026.
Q1 2025 net income $43.1M (basic EPS $5.12); diluted net loss per share ($2.11) due to warrant fair value change.
Phase 2 B-SUPREME study of ALG-000184 in chronic HBV expected to begin mid-2025; interim data 2026, topline 2027.
ALG-055009 (THR-β agonist) Phase 2a HERALD showed placebo-adjusted median liver fat reduction up to 46.2%; up to 70% subjects achieved ≥30% reduction.
ALG-097558 pan-coronavirus inhibitor has 3 clinical trials ongoing; NIAID study Q2 2025. Company seeking external funding for further development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.